Year: 2022
Type: editorial
Abstract: In this issue of Blood, Zhao et al report that downregulation of MS4A3 contributes to the persistence, progression, and drug resistance of chronic myeloid leukemia (CML) to the BCR-ABL inhibitor imatinib. 1Thus, enhancing MS4A3 levels provides a potential therapeutic strategy in treating CML.
Source: Blood
Authors: Kaosheng Lv, Wei Tong
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Regulation of protein ubiquitination in hematopoietic cytokine signaling, Lnk Regulatory Functions in Hematopoietic Stem Cells, Regulation of Ribosome Biogenesis in Hematopoietic Stem Cells, Regulation of FLT3 Signaling in Leukemia, Novel Regulation of Oncogenic NRAS Signaling in Myeloid Malignancies
OpenAlex ID: W4210777535